Moreadith Randall 4

What Happened
Moreadith Randall, Chief Scientific Officer of Serina Therapeutics (SER), exercised stock options and sold 6,500 shares on 2026-03-23. She paid $0.06 per share ($390 total) to acquire 6,500 shares via option exercise (transaction code M) and then sold those 6,500 shares in open-market trades at a weighted average price of $2.86 per share, receiving about $18,568 (transaction code S). The filing also reports a derivative conversion/disposition of 6,500 shares at $0.00 (reported as a disposition of a derivative instrument).

Key Details

• Transaction date: 2026-03-23 (Form 4 filed 2026-03-24) — filing appears timely.
• Option exercise: 6,500 shares acquired at $0.06/share — total exercise cost $390. (Footnote F2: the options were fully vested.)
• Open-market sale: 6,500 shares sold at a weighted avg $2.86/share — proceeds ~$18,568. (Footnote F1: sale prices ranged from $2.68 to $3.03; weighted average reported.)
• Derivative disposition: 6,500 shares reported as disposed at $0.00 (listed separately on the Form 4).
• Shares owned after transaction: not provided in the summary data supplied here.
• Transaction codes: M = option exercise; S = open-market sale.

Context

• This was effectively a same-day exercise-and-sell (cashless-style) transaction: the reporting person exercised options and sold the resulting shares the same day. Such transactions are commonly used to cover exercise costs or diversify holdings and are routine for insiders; they do not, by themselves, indicate the insider’s view of the company’s long-term prospects.